Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBio-Sustainable Future Enterprises Regulatory News (BSFA)

Share Price Information for Bio-Sustainable Future Enterprises (BSFA)

Share Price is delayed by 15 minutes
Get Live Data
1.025    0.025 (2.50%)
Bid:
0.80
Ask:
1.25
Spread: 0.45 (56.25%)
Market Cap: £1.99m
BSFA Live PriceLast checked at - London Stock Exchange

Intraday Bio-Sustainable Future Enterprises Share Chart

First Tannable A4-Sized Skin Achieved

10 Mar 2026 10:47

RNS Number : 0672W
BSF Enterprise PLC
10 March 2026
 

10 March 2026

BSF Enterprise PLC

First Tannable A4-Sized Skin Achieved

Scalable Process Unlocked for Elemental™; T-Rex Leather™ Showcase Confirmed for 2 April 2026

BSF Enterprise PLC (LSE:BSFA), the tissue-engineering innovator, is pleased to report a significant commercial milestone for its wholly-owned subsidiary Lab-Grown Leather Limited ("LGL"): the successful production of a fully tanned, scaffold-free skin reaching A4 sheet size and approaching 2mm thickness - achieved in a matter of weeks using LGL's proprietary Advanced Tissue Engineering Platform ("ATEP™").

 

Key Milestones Achieved

• A4-size tannable skin produced at industrially relevant thickness (~2mm)

• Scalable process developed over the last six months using ATEP™

• Scaffold-free architecture delivering bio-equivalent durability, breathability and patina

• Zero-waste geometry: skin cultivated to specification, eliminating traditional hide scrap rates

• T-Rex Leather™ website and social channels live; showcase event confirmed for 2 April 2026

 

Elemental™: A New Standard for High-Performance Luxury Materials

The Elemental™ product series represents the commercial embodiment of LGL's ATEP™. Over the past six months, the LGL team has engineered a repeatable, scalable process that takes animal cells and cultivates them into a tannable skin product at dimensions that are meaningful to luxury goods manufacturers. This first full tanning of the material - a critical processing step required before leather can be used in finished goods - confirms that Elemental™ is advancing through the technical readiness pathway towards commercial supply.

 

Unlike many competing bio-based or synthetic alternative materials, LGL's scaffold-free approach means the cells self-organise to produce a material that is bio-equivalent to conventional hide: retaining the structural integrity, tactile properties, and characteristic patina that luxury brands demand. The process can be tuned to produce leathers that are thinner, stronger, or with unique surface characteristics that would be impossible or unethical to source conventionally. Thus LGL is able to uniquely position ElementalTM as a high-end, low-intervention material, setting the standard for a new generation of leather and cultivating a new era for luxury.

 

T-Rex Leather™ - Where Technology Meets Rarity

One of the most distinctive and commercially compelling applications of LGL's platform is its ability to engineer material inspired by the cellular biology of rare and extinct species. T-Rex Leather™ leverages this capability to offer the luxury and fashion industries access to materials that are, by definition, unavailable by any other means - creating a genuine scarcity narrative that is entirely authentic and ethically sound.

 

This positions LGL in a unique category: not simply a "more sustainable" version of existing leather, but a genuinely new class of luxury material with intrinsic rarity, provenance, and a powerful story. The T-Rex Leather™ brand has now launched its website and social media presence, and a showcase event has been confirmed for 2 April 2026, which the Company expects to generate significant press and industry engagement.

See links:

https://www.instagram.com/t_rex_leather/

https://lab-grown-leather.com/t-rex-leather/

 

Elemental™ skin sample - A4 size, approaching 2mm thickness

Commercial Outlook

The achievement of a tannable skin at A4 scale and industrially relevant thickness is a key gate in LGL's commercialisation roadmap. The Company is now in a position to extend its engagement with luxury goods manufacturers, material distributors, and brand partners on the basis of a tangible, scalable and demonstrable product. LGL's IP-protected ATEP™ platform provides a defensible competitive moat across both the conventional luxury leather market and the emerging exotic/extinct species segment.

 

The Company will continue to update shareholders on progress, including the outcome of the 2 April 2026 T-Rex Leather™ showcase event.

 

END

 

Engage with the BSF Enterprise management team directly by asking questions, watching videosummaries and seeing what other shareholders have to say. Navigate to our Interactive Investorwebsite here:

 

https://bsfenterprise.com/link/ya3aRr

 

For further enquiries, please visit www.bsfenterprise.com or contact:

 

BSF Enterprise PLC

Geoff Baker - Chairman

Che Connon - CEO & Director

 

We encourage all investors to share questions on this announcement via our investor website.

https://bsfenterprise.com/s/a1f22b

Shard Capital (Broker)

Damon Heath

Isabella Pierre

 

0207 186 9000

0207 186 9927

AlbR Capital Limited (Broker)

Colin Rowbury

Jon Belliss

+44 (0)20 7469 0930

ISIN of the Ordinary Shares

is GB00BHNBDQ51.

SEDOL Code is BHNBDQ5.

 

 

 

Subscribe to our news alert service: https://bsfenterprise.com/s/bb9f43

 

About BSF Enterprise PLC

BSF Enterprise PLC (LSE:BSFA) develops and commercialises cutting-edge tissue-engineered solutions, including lab-grown leather (via LGL), cultivated meat, and corneal repair technologies. By leveraging its proprietary scaffold-free ATEP™ platform, BSF delivers sustainable, high-performance alternatives to conventional materials, targeting global markets where provenance, ethics, and performance are increasingly prized by consumers and brands alike.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBGGDXBSBDGLG
Date   Source Headline
10th Feb 20237:00 amRNSAllotment of shares
1st Feb 20234:40 pmRNSSecond Price Monitoring Extn
1st Feb 20234:35 pmRNSPrice Monitoring Extension
1st Feb 20232:05 pmRNSSecond Price Monitoring Extn
1st Feb 20232:00 pmRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSUK’s First Fillet of Cultivated Meat Produced
31st Jan 20234:36 pmRNSAnnual Report and Financial Statements
19th Dec 20227:00 amRNS3D Bio-Tissues enters partnership with New Harvest
23rd Nov 20224:40 pmRNSSecond Price Monitoring Extn
23rd Nov 20224:36 pmRNSPrice Monitoring Extension
23rd Nov 20227:00 amRNS3D Bio-Tissues partners with cell growth company
15th Nov 20227:00 amRNSSuccessful Prototypes of Lab-Grown Fillets of Meat
27th Oct 20227:00 amRNS3D Bio-Tissues receives €100,000 grant
21st Sep 20227:00 amRNS3D Bio-Tissues Appoints Business Director
18th Jul 20227:00 amRNSOperational Update
12th Jul 202212:08 pmRNSResults of Annual General Meeting
29th Jun 20227:00 amRNSInterim Financial Statements
17th Jun 20221:43 pmRNSNotice of Annual General Meeting
6th Jun 202210:42 amRNSAppointment of new CFO and opening London Office
17th May 20228:00 amRNSAdmission to Trading and First Day of Dealings
16th May 202210:46 amRNSResults of General Meeting
27th Apr 202212:07 pmRNSConditional Placing to raise £1.75 million
14th Feb 20224:52 pmRNSAnnual Financial Report
24th Dec 202110:58 amRNSAcquisition
16th Aug 20218:13 amRNSProposed Transaction and Suspension of Listing
16th Aug 20217:30 amRNSSuspension - BSF Enterprise Plc
9th Aug 20217:00 amRNSAppointment of Director
4th May 20212:44 pmRNSHalf-year Report
23rd Apr 202112:13 pmRNSHalf-year Report
6th Apr 20218:37 amRNSCorrection Statement
1st Apr 20214:56 pmRNSAGM Statement
1st Apr 20214:54 pmRNSResult of AGM
1st Apr 20217:00 amRNSAnnual Financial Report
1st Apr 20217:00 amRNSNotice of AGM
4th Mar 20213:19 pmRNSAGM Statement
4th Aug 20207:00 amRNSResult of General Meeting 
16th Jul 20207:48 amRNSAcquisition
31st Mar 20207:00 amRNSResult of AGM
26th Mar 202010:49 amRNSNotice Of AGM
3rd Mar 20204:10 pmRNSNotice of Annual General Meeting 2020
3rd Feb 20207:00 amRNSAnnual Financial Report
26th Jul 20198:31 amRNSFirst Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.